Patents by Inventor Jonathan D. Oliner

Jonathan D. Oliner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
    Publication number: 20220280495
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: September 9, 2021
    Publication date: September 8, 2022
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
    Patent number: 10881648
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 5, 2021
    Assignee: AMGEN INC.
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
    Publication number: 20190290630
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 26, 2019
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
    Publication number: 20160287569
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: November 11, 2014
    Publication date: October 6, 2016
    Applicant: AMGEN INC.
    Inventors: Sean CAENEPEEL, Jude CANON, Paul HUGHES, Jonathan D. OLINER, Anne Y. SAIKI, Richard J. RICKLES
  • Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 and Uses Thereof
    Publication number: 20120258122
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 11, 2012
    Inventors: Thomas C. Boone, Jonathan D. Oliner
  • Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
    Patent number: 8221749
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: July 17, 2012
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Jonathan D. Oliner
  • Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
    Publication number: 20120034237
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 9, 2012
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, Jonathan D. OLINER
  • Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
    Patent number: 8030025
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: October 4, 2011
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Jonathan D. Oliner
  • Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
    Publication number: 20090226447
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Application
    Filed: February 19, 2009
    Publication date: September 10, 2009
    Applicant: Amgen, Inc.
    Inventors: Thomas C. Boone, Jonathan D. Oliner
  • Determining signal transduction pathways
    Patent number: 6746844
    Abstract: Experimental and analytical methods enable reconstruction of signal transduction networks from gene expression profiles. Signal transduction pathways can be reverse-engineered by 1) experimentally manipulating individual genes, 2) generating cellular expression profiles, and 3) analyzing for common patterns among these profiles. Analysis of patterns among profiles permits reconstruction of pathways and networks of interrelationships among genes and their products.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: June 8, 2004
    Assignee: Affymetrix, Inc.
    Inventors: Jonathan D. Oliner, Earl Hubbell
  • Determining signal transduction pathways
    Publication number: 20020094518
    Abstract: Experimental and analytical methods enable reconstruction of signal transduction networks from gene expression profiles. Signal transduction pathways can be reverse-engineered by 1) experimentally manipulating individual genes, 2) generating cellular expression profiles, and 3) analyzing for common patterns among these profiles. Analysis of patterns among profiles permits reconstruction of pathways and networks of interrelationships among genes and their products.
    Type: Application
    Filed: January 22, 2002
    Publication date: July 18, 2002
    Applicant: Affymetrix, Inc.
    Inventors: Jonathan D. Oliner, Earl Hubbell
  • Determining signal transduction pathways
    Patent number: 6340565
    Abstract: Experimental and analytical methods enable reconstruction of signal transduction networks from gene expression profiles. Signal transduction pathways can be reverse-engineered by 1) experimentally manipulating individual genes, 2) generating cellular expression profiles, and 3) analyzing for common patterns among these profiles. Analysis of patterns among profiles permits reconstruction of pathways and networks of interrelationships among genes and their products.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: January 22, 2002
    Assignee: Affymetrix, Inc.
    Inventors: Jonathan D. Oliner, Earl Hubbell